Nureca Limited concludes GST dispute with ₹15.4 lakh payment
Nureca Limited resolved a GST dispute for the 2021-22 period by reversing Input Tax Credit worth Rs. 15,40,311. The Final Order of Rectification under the CGST Act confirms no further demands exist. The disclosure was made under SEBI LODR Regulations.

*this image is generated using AI for illustrative purposes only.
Nureca Limited has concluded a pending Goods and Services Tax (GST) dispute by receiving a Final Order of Rectification under Section 161 of the CGST Act, 2017. The resolution pertains to a tax order for the period 2021-22 and was finalized on August 07, 2026, following the payment of outstanding dues. This closure eliminates any further regulatory demand from the concerned authority regarding this specific tax period.
The settlement was achieved through the reversal of Input Tax Credit (ITC) rather than a cash outflow, preserving the company’s immediate liquidity position. The total value of the dues settled amounted to Rs. 15,40,311. By opting for ITC reversal, Nureca Limited addressed the compliance requirement while managing its working capital efficiently, a common strategy in indirect tax disputes where credit balances are available.
Settlement Details
The financial impact of the resolution is limited to the reversal of tax credits, as detailed below:
| Particulars | Amount |
|---|---|
| Dues Paid via ITC Reversal | Rs. 15,40,311 |
| Tax Period Covered | 2021-22 |
| Regulatory Framework | CGST Act, 2017 |
Regulatory Disclosure
Nureca Limited made this disclosure pursuant to Regulation 30(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The announcement was issued to both the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE) to ensure transparency with investors. The notice was signed by Nishu Kansal, Company Secretary & Compliance Officer, confirming that the matter stands fully concluded with no further liabilities arising from the original order.
What the Numbers Show
The use of Input Tax Credit reversal to settle the Rs. 15,40,311 liability indicates that the dispute did not result in an additional cash burden for the company. In GST litigation, settlements often involve penalties or interest payments in cash; however, a pure ITC reversal suggests the core issue was likely related to the eligibility or matching of input credits rather than a fundamental evasion of tax liability. This outcome neutralizes the regulatory risk associated with the 2021-22 period without impacting the company’s cash flow statement.
Historical Stock Returns for Nureca
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.87% | +4.19% | +46.57% | +21.19% | +44.08% | -80.57% |
How might the successful resolution of this GST dispute influence Nureca Limited's future tax compliance strategies and internal audit processes?
Could the precedent set by settling via Input Tax Credit reversal encourage other pharmaceutical companies to adopt similar non-cash settlement methods for indirect tax disputes?
What impact, if any, will the removal of this regulatory overhang have on Nureca Limited's credit ratings or investor sentiment regarding its operational risk profile?


































